VivoSeq
Dermatology

Basal Cell Nevus Syndrome

0

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Basal Cell Nevus Syndrome is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

33/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed4 · 67%
Terminated1 · 17%
Withdrawn1 · 17%

Clinical Trials

Trial Activity

6 trials

Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome
Completed·UUniversity Health Network, Toronto·N/A·NCT02100371·2 enrolled
Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants
Completed·YYale University·Phase 1·NCT00433485·16 enrolled
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
Completed·UUCSF Benioff Children's Hospital Oakland·Phase 2·NCT00957229·41 enrolled
Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome
Completed·—·N/A·NCT02157623·3 enrolled
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Terminated·SSol-Gel Technologies, Ltd.·Phase 3·NCT04308395·108 enrolled
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
Withdrawn·—·Phase 2·NCT03767439

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)